What LIGAND PHARMACEUTICALS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 40 | 151 |
| Total trades | 43 | 222 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 5,340 | 214,568 |
| Disposed | 24,208 | 195,993 |
| Net activity | −18,868 | +18,575 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kozarich John W | Director | Nov 12 | Disclosed 10b5-1 sale · S | −500 | $325.00 | −$163K | 42,122 |
| Zimmermann Martine | Director | Nov 12 | Open-market sale · S | −2,000 | $318.17 | −$636K | 1,782 |
| Aryeh Jason | Director | Nov 10 | Open-market sale · S | −500 | $320.20 | −$160K | 105,476 |
| Aryeh Jason | Director | Nov 10 | Open-market sale · S | −500 | $320.10 | −$160K | 105,976 |
| Aryeh Jason | Director | Nov 10 | Open-market sale · S | −10 | $320.02 | −$3.2K | 106,476 |
| Aryeh Jason | Director | Nov 10 | Open-market sale · S | −646 | $320.00 | −$207K | 106,486 |
| Aryeh Jason | Director | Nov 10 | Open-market sale · S | −844 | $320.00 | −$270K | 107,132 |
| Aryeh Jason | Director | Nov 10 | Open-market sale · S | −500 | $319.99 | −$160K | 107,976 |
| Aryeh Jason | Director | Nov 04 | Open-market sale · S | −282 | $319.99 | −$90.2K | 108,476 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −120 | $323.14 | −$38.8K | 31,854 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −200 | $321.44 | −$64.3K | 31,974 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −320 | $319.97 | −$102K | 32,174 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −440 | $318.73 | −$140K | 32,494 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −280 | $317.91 | −$89K | 32,934 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −80 | $314.58 | −$25.2K | 33,214 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −403 | $313.75 | −$126K | 33,294 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −634 | $312.85 | −$198K | 33,697 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −520 | $311.72 | −$162K | 34,331 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −490 | $310.61 | −$152K | 34,851 |
| Reardon Andrew | CLO & Secretary | Nov 02 | Disclosed 10b5-1 sale · S | −522 | $309.91 | −$162K | 35,341 |
Loading...